Literature DB >> 11788051

Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels.

D M Wilcock1, M N Gordon, K E Ugen, P E Gottschall, G DiCarlo, C Dickey, K W Boyett, P T Jantzen, K E Connor, J Melachrino, J Hardy, D Morgan.   

Abstract

There have been several reports on the use of beta-amyloid (Abeta ) vaccination in different mouse models of Alzheimer's disease (AD) and its effects on pathology and cognitive function. In this report, the histopathologic findings in the APP+PS1 doubly transgenic mouse were compared after three, five, or nine Abeta inoculations. The number of inoculations influenced the effects of vaccination on Congo red levels, microglia activation, and anti-Abeta antibody titers. After three inoculations, the antibody titer of transgenic mice was substantially lower than that found in nontransgenic animals. However, after nine inoculations, the levels were considerably higher in both genotypes and no longer distinguishable statistically. The number of inoculations influenced CD45 expression, an indicator of microglial activation. There was an initial upregulation, which was significant after five inoculations, but by nine inoculations, the extent of microglial activation was equivalent to that in mice given control vaccinations. Along with this increased CD45 expression, there was a correlative reduction in staining by Congo red, which stains compact plaques. When data from the mice from all groups were combined, there was a significant correlation between activation of microglia and Congo red levels, suggesting that microglia play a role in the clearance of compact plaque.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11788051     DOI: 10.1089/10445490152717596

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  31 in total

1.  CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice.

Authors:  Yuyan Zhu; Huayan Hou; Kavon Rezai-Zadeh; Brian Giunta; Amanda Ruscin; Carmelina Gemma; Jingji Jin; Natasa Dragicevic; Patrick Bradshaw; Suhail Rasool; Charles G Glabe; Jared Ehrhart; Paula Bickford; Takashi Mori; Demian Obregon; Terrence Town; Jun Tan
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

2.  Abnormal post-translational and extracellular processing of brevican in plaque-bearing mice over-expressing APPsw.

Authors:  Joanne M Ajmo; Lauren A Bailey; Matthew D Howell; Lisa K Cortez; Keith R Pennypacker; Hina N Mehta; Dave Morgan; Marcia N Gordon; Paul E Gottschall
Journal:  J Neurochem       Date:  2010-02-17       Impact factor: 5.372

Review 3.  Biomarkers in Alzheimer's disease: past, present and future.

Authors:  Katarzyna Gustaw-Rothenberg; Alan Lerner; David J Bonda; Hyoung-gon Lee; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

4.  Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease.

Authors:  Dan Frenkel; Ruth Maron; David S Burt; Howard L Weiner
Journal:  J Clin Invest       Date:  2005-08-11       Impact factor: 14.808

Review 5.  Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype mice.

Authors:  Cynthia A Lemere; Edward T Spooner; Jodi F Leverone; Chica Mori; Melitza Iglesias; Jeanne K Bloom; Timothy J Seabrook
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

6.  Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition.

Authors:  Donna M Wilcock; Amyn Rojiani; Arnon Rosenthal; Gil Levkowitz; Sangeetha Subbarao; Jennifer Alamed; David Wilson; Nedda Wilson; Melissa J Freeman; Marcia N Gordon; Dave Morgan
Journal:  J Neurosci       Date:  2004-07-07       Impact factor: 6.167

Review 7.  Immunotherapy for Alzheimer's disease.

Authors:  David S Gelinas; Kevin DaSilva; Daniela Fenili; Peter St George-Hyslop; Joanne McLaurin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

8.  Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial.

Authors:  Hayk Davtyan; Anahit Ghochikyan; Irina Petrushina; Armine Hovakimyan; Arpine Davtyan; Anna Poghosyan; Annette M Marleau; Nina Movsesyan; Anatoly Kiyatkin; Suhail Rasool; Anna Kirstine Larsen; Peter Juul Madsen; Karen Malene Wegener; Dorte Kornerup Ditlevsen; David H Cribbs; Lars Ostergaard Pedersen; Michael G Agadjanyan
Journal:  J Neurosci       Date:  2013-03-13       Impact factor: 6.167

9.  Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.

Authors:  Suhail Rasool; Hilda Martinez-Coria; Jessica W Wu; Frank LaFerla; Charles G Glabe
Journal:  J Neurochem       Date:  2013-06-16       Impact factor: 5.372

Review 10.  Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.

Authors:  Donna M Wilcock; Carol A Colton
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.